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Abstract 
The NICE reference case has received widespread acceptance in health technology assessment. The lifetime cost-per-QALY model and 
constructed claims for product impact have been widely emulated in country-specific guidelines for formulary submission as well as in 
publications in the leading health technology journals. Unfortunately, from the perspective of the standards of normal science, 
adherence to the reference case standard means that the claims made are typically non-evaluable. They have to be taken at face 
value. They may suggest potential evaluable hypotheses for clinical and cost-effectiveness claims, but there is no requirement in the 
reference case for  claims to be put in an evaluable form and for manufacturers to suggest possible protocols for product impact 
assessment. This is not an acceptable situation. Absent the standards for falsification and replication, which are at the core of the 
scientific method, we have no idea whether the claims accepted by NICE are right or even if they are wrong. If we accept the 
reference case paradigm should we conclude that the sunlit uplands of formulary decisions based on non-evaluable simulated claims 
for cost-effectiveness has been reached? Have we rejected natural selection in favor of intelligent design? 
 
Keywords: NICE, reference case, cost-effectiveness, cost-utility, modeling, credibility, imaginary worlds, scientific method 
 
 
 
Introduction 
The National Institute for Health and Care Excellence (NICE) 
has an enviable reputation. Since its formation in the late 
1990s (and after a name change) it has assumed a leadership 
role in health technology assessment. This is due, not only to 
the resources allocated to its range of activities, but to its 
application of a reference case model to the process health 
technology assessment; a reference standard for health 
technology assessment that has been widely accepted 1  2  3. 
The purpose of this review is to consider whether or not the 
reference case approach to health technology assessment 
has merit. Specifically, are the standards and processes of 
reference case evaluations for pharmaceutical products and 
devices compatible with what may be described as the 
scientific method? If they are not, are there possible 
explanations for the ongoing advocacy of the reference case 
methodology and its central role in NICE recommendations 
for formulary acceptance?   
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The scientific method is not new; it can be traced back at 
least 350 years to the work of Bacon, Galileo, Boyle, 
Descartes and Newton 4. The essence of the scientific method 
is captured in the motto of the Royal Society (founded 1660; 
Royal Charter 1662): Nullius in Verba (“take no man’s word 
for it”). Unless there is the ability to test a hypothesis and if 
that hypothesis is tested, then we have some confidence in 
the worth of the hypothesis. Otherwise, the claim should not 
be taken at face value; irrespective of how reasonable and 
appealing it might be 5. Popper has made abundantly clear 
the worth of the scientific method in his advocacy of the 
falsification hypothesis: a theory in the empirical sciences can 
never be proven 6  7. It must be scrutinized by decisive 
experiments 8. Theories that survive are not more ‘true’, they 
are more ‘fit’ for the problem at hand. For Popper it is from 
the interplay between the tentative theories (conjectures) 
and error elimination (refutation) that scientific knowledge 
advances. As Popper notes: ‘non-reproducible single 
occurrences are of no significance to science’. 
Experimentation is central: a process described in a recent 
issue of Science as one where ‘The deepest trust in scientific 
knowledge comes from the ability to replicate empirical 
findings directly and independently, whether through 
reanalyzing original data or by creating new data’ 9. 
 
Irrespective of whether or not we are developing hypotheses 
regarding the impact of minimum wage proposals on 
employment, the impact of rent control on the quality of a 
housing stock or the clinical and cost-effectiveness claims of 
competing pharmaceutical products, the scientific method 
dictates that they be presented in evaluable terms. In the 
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absence of experimental evidence, or the potential to 
demonstrate an experimental result, we have no idea, as 
Wolfgang Pauli has said, whether the claims made are right or 
even if they are wrong 10. The key question for NICE is 
whether their standards for technology assessment are 
consistent with the standards of normal science or reflect 
acceptance of a relativist position in evidence-based decisions 
 
The Reference Case 
The NICE reference case requires submission for product 
review to conform to the following standards: 
• Decision problem as defined by NICE scope 
• Comparator therapies are those listed in the NICE 
scope 
• Required to include of all direct health effects for 
patients and caregivers 
• Costs are those incurred by the NHS and PPS 
• Required cost-utility analysis with fully incremental 
analysis 
• Required time horizon long enough to reflect all 
important differences in costs and outcomes 
between technologies being compared 
• Claims for health effects to be based on a systematic 
review 
• Health effects to be expressed as quality adjusted 
life years (QALYs) with the EQ-5D the preferred 
instrument 
• Data for measurement of health related quality of 
life should be that reported by patients and/or 
caregivers 
• Preference data for valuation of changes in health 
related quality of life should be from a 
representative sample of UK population 
• QALYs all have equal equity weight 
• Resource use and costs should be valued using prices 
relevant to NHS and PPS 
• Costs and benefits should be discounted at same 
annual rate (3.5%) 
 
The reference case requires the decision model time horizon 
to be sufficiently long ‘to reflect all important differences in 
costs and outcomes between the technologies being 
considered’.  For NICE, as many technologies have an impact 
over the lifetime of a patient, a lifetime horizon is usually 
appropriate. Noting also that ‘analyses that limit the time 
horizon to periods shorter than the expected impact of 
treatment do not usually provide the best estimates of 
benefits and costs’.  
 
Application of NICE reference case standards, in the case of 
chronic disease interventions, results in a model or simulation 
that attempts to mimic the natural progression of the disease 
and the impact of competing interventions over the patient’s 
lifetime or similar long-term time horizon. Stages of disease 
progression are captured by, for example, a Markov process 
which tracks the hypothetical cohort of patients through the 
disease stages. Each health state is defined in terms of 
associated utilities and costs. The results in scenario driven 
claims expressed in cost-per-QALY terms. By application of a 
willingness-to-pay threshold cost-per-QALY, products are 
either judged acceptable, rejected or accepted after 
agreement on a discounted price. 
 
Responding to the Reference Case 
Following the reference case criteria, a manufacturer typically 
prepares a modeled or simulated clinical and cost-utility case 
for their product. In a single technology appraisal (STA) the 
comparator is usually the standard of care. Understandably, 
the submission is inclined to put the manufacturer’s product 
in a positive light in order to support the suggested product 
price. The manufacturer would endeavor also to claim 
consistency with standard proposed by the International 
Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) And the CHEERS and similar input quality check lists 11 
12  13.  
 
Consider, as case studies in the application of the reference 
case, models developed to support the marketing of the four 
novel anti-coagulants (NOAC); dabigatran, rivaroxaban, 
apixaban and endoxaban. NICE has undertaken four single 
technology assessments of these products 14  15  16  17. The 
process of assessment is in three stages: (i) the manufacturer 
submits its model; (ii) the model is evaluated by an academic 
or similar evidence review group (ERG) that consider the 
model structure, the input assumptions, the basis for the 
assumptions and the possibility of sub-group analyses; and 
(iii) the reviewers comments and possible reformulation of 
the model are then assessed by the NICE Advisory 
Committee. A final version of the model or simulation is 
agreed together with the modeled claims for utility scores, 
costs (both discounted) and incremental cost-per-QALY 
scores. These imaginary scores are then applied to a NICE 
determined willingness to pay cost-per-QALY threshold 
(usually £20,000). At no stage is the issue of evaluating the 
claims raised. 
 
The various NOAC models, extrapolating from their 
respective Phase 3 clinical trials, all adopted the 
recommended lifetime Markov framework. Discrete health 
states reflecting the range of possible adverse events (bleeds, 
stroke) were proposed together with cycle length (3 months 
or 1-year). Transition probabilities were estimated from the 
Phase 3 trials and the literature. Assumptions, often trial 
based, for therapy discontinuations were imposed. Utilities 
for the health states were constructed from the literature, 
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together with estimated direct medical costs for each health 
state. Utilities and costs, apart from an age-utility decrement 
factor, are invariant over the lifetime of the model; both are 
discounted. Then, voilà, base-case and supplementary ICERs 
emerge yielding QALY estimates, lifetime costs and cost-per-
QALY estimates to set against the willingness to pay 
threshold. 
 
In the case of edoxaban, the constructed discounted 
probabilistic cost-utility outcomes estimated by the ERG from 
the manufacturer’s base case model yielded a lifetime cost 
per QALY for warfarin of £12,868 and a lifetime QALY gain of 
6.56 years. The constructed results for edoxaban were 
£15,451 and QALY gain of 6.72; an increment of discounted 
58 quality days over the lifetime of those initiated to 
edoxaban rather than warfarin. Corresponding constructed 
QALY estimates for the other NOACS were: rivaroxaban 6.65, 
dabigatran 110mg 6.66, dabigatran 150mg 6.75 and apixaban 
6.77. Differences between the lowest QALY NOAC and the 
highest QALY NOAC (rivaroxaban vs. apixaban) is 76 quality 
lifetime days. Constructed discounted lifetime costs were 
rivaroxaban £16,313, dabigatran 110mg £15,732, dabigatran 
150mg £15,293 and apixaban £15,531. The reviewers 
concluded that ‘edoxaban, dabigatran etexilate 110 mg and 
rivaroxaban were strictly dominated by dabigatran etexilate 
150 mg and apixaban extendedly dominated dabigatran 
etexilate 150 mg (more effective and less costly) with an ICER 
of £13,036 per QALY gained compared to warfarin’.   
 
After the manufacturer’s submission, the ERG assessment by 
the Liverpool Reviews and Implementation Group (LRiG), 
involving eleven reviewers, the ‘evidence’ was considered by 
the Appraisal Committee on whether or not the claimed ICER 
met the willingness-to-pay threshold 19. The Appraisal 
Committee noted that the warfarin monitoring costs were 
the main cost driver in the cost-effectiveness analysis. 
Unfortunately, there was no agreement on what that cost 
might be. The Appraisal Committee considered that the ICER 
relative to warfarin was likely to be closer to the ERG 
estimate of £26,000 per QALY compared to the company 
estimate of £2,500 per QALY. However, due to perceived 
flaws in the company model and the lack of definitive 
warfarin monitoring costs the committee could not accept 
the lower estimate. At the same time the upper ICER was 
considered uncertain. In a Solomon-like decision the 
Appraisal Committee concluded that, as the clinical evidence 
was similar to the other NOACs previously reviewed and the 
price of edoxaban was similar to rivaroxaban, it was likely 
that the plausible (but unknown) ICER for edoxaban was likely 
to be in line with the other NOACs. Edoxaban could therefore 
be recommended as a cost-effective use of NHS resources. 
 
On the face of it nothing could be simpler or more 
compelling. The precision of these constructed results for 
these projected lifetime discounted costs and QALYs is 
impressive; certainly more impressive than a 10-day weather 
forecast or economists’ projections for GDP growth in the 
next 12 months (which are invariably incorrect). The evidence 
base for the input assumptions is well documented and the 
disease stages reflect the clinical process of the disease. If this 
correspondence with the real world is agreed by the 
academic review group and the NICE advisory committee to 
be sufficient, then the necessary cost-utility outcome is 
entailed 18. 
 
Obviously these cost and QALY claims are not only 
constructed but are impossible to put in testable terms for 
empirical assessment and replication. The current NHS costs 
identified for the reference case are expected to remain 
unchanged (apart from discounting) over the modeled time 
horizon. Estimated lifetime costs can only be challenged by 
challenging cost assumptions. The QALY estimates are 
typically based on the literature. In the case of edoxaban 
while the initial event quality of life estimate was trial based 
all subsequent utilities for the treatment and event stages in 
the Markov 2-week cycle model were literature based.  
 
If we accept the reference case methodology as appropriate 
for formulary decisions it seems reasonable to conclude that 
there was never any intention that the reference case should 
generate evaluable claims. After all, QALYs are not collected 
in the UK by regional health authorities and, as far as can be 
judged, these health authorities have no interest in collecting 
QALYs. Decisions were to be based on constructed evidence. 
Any dispute over the claims made could only be resolved by 
challenging the model or simulation. Given this, the question 
is then one of whether we have crossed the boundary 
between science and pseudoscience; rejecting natural 
selection in favor of intelligent design? 20 
 
Truth is Consensus 
But perhaps we are being unreasonable. Perhaps NICE in its 
advocacy of the reference case is not rejecting the scientific 
method but taking a relativist position. Rather than 
subscribing to the position that the standards of normal 
science are the only standards to apply in health care 
decisions, the relativist believes that all perspectives are 
equally valid. In their advocacy of the equivalence or 
symmetry, health care decisions are to be understood 
sociologically. No one body of evidence is superior to 
another. Results of a simulation are on an equal basis with 
those of a randomized clinical trial (RCT). For the relativist the 
success of a scientific research program, in this case one built 
on models and simulations, rests not on its ability to generate 
new knowledge but on its ability to mobilize the support of a 
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community. Basing decisions on models and simulations 
underpins the consensus view that evidence is constructed, 
never discovered. Instead of coming to grips with reality, 
science is about rhetoric, persuasion and authority. Truth is 
consensus. 
 
From this perspective, the construction of evidence in the 
modeled or simulated chronic disease environment is readily 
understandable. There is no need to discover new facts. 
Supported by a community of academic advisors and 
professional organizations, NICE embraces the relativist 
position. Simulations or models are accepted because in the 
consensus view, the view of the authorities in the discipline, 
including academics from leading technology assessment 
groups, the ability to capture the assumed critical or similar 
features of the reality of a decision is all that is required. The 
mandated reference case is to demonstrate who is in the 
driving seat. Reality is achieved through rhetoric, persuasion 
and authority.  
 
The simulations are, for NICE, the reality of the decision 
environment. Unlike the Royal Society we have to take their 
word for it. The simulations are seen as sufficient to support 
formulary decisions with the claims for competing products 
necessarily entailed by the model assumptions and core 
mechanism. Any thoughts of interplay between tentative 
theories (conjectures) and error elimination (refutation), the 
process of the discovery of new facts, are not only put to one 
side but they are irrelevant. The broad, sunlit upland of non-
evaluable cost-effectiveness decisions based on constructed 
evidence has been reached. 
 
Stimulations Can Fail 
But simulations can be challenged; simulations can fail. 
Practically, there is unlikely to be agreement on 
correspondence, sufficiency and necessary entailment. 
Practitioners can agree that a Markov process is appropriate 
to capture the natural course of a disease, yet disagree on the 
cycle length, the number of health states and transition 
probabilities that the model accommodates. The flexibility 
allowed in constructing simulations means that simulations, 
by their nature, can always be challenged. Indeed, any 
number of competing simulations coming to different 
conclusions, are entirely possible. Rather than capturing the 
essence of a decision problem, the simulation captures the 
perception of the essence of the problem held by the authors 
of the simulation guided by an existential reference case or 
similar standards. In the last resort, the validation of one 
simulation can only be achieved by matching to the 
performance of another. 
 
Consider the novel oral anticoagulant (NOAC) case. A recent 
study by Yao et al compares adherence patterns for warfarin 
with those for rivaroxaban, dabigatran and apixaban and 
their impact on risk of stroke and major bleeding 21. During a 
median follow up of 1.1 years, only 47.5% of NOAC patients 
were adherent, defined as a medication possession ratio 
(MPR) of ≥ 80% of therapy days. Adherence to warfarin was 
40.2%. Apixaban had the highest unadjusted adherence 
(61.9%) and dabigatran the lowest (38.5%). The rivaroxaban 
rate was 58.4%. Applying a multivariate logistic regression, 
adjusted adherence rates were 38.7% for warfarin and 47.5% 
for all NOACs. Higher rates of adherence were found across 
all treatments for those at higher risk. For those with a 
CHAa2DS2-VASc ≥ 4 the warfarin adherence was 53.4% and 
the average for the NOACs 59.8%. 
 
Persistence with NOACs has been reported in three recent 
observational studies. Forslund et al utilizing data from the 
administrative health register of the Stockholm region 
evaluated crude and adjusted persistence from the index OAC 
prescription in the period April 2011 to December 2014 22. At 
the end of the first year crude overall persistence was 88.2% 
and 82.9% at the end of the second year. Persistence with 
warfarin at the end of the first year was 85.0%, apixaban 
85.9%, dabigatran 74.4% and rivaroxaban 77.4%. In the UK, 
Martinez et al reported on persistence with longitudinal data 
from the Primary Care Clinical Practice Research Datalink 
between January 2011 and May 2014  . Persistence with 
warfarin at the end of the first year was 63.6$ and 79.2% for 
all NOACs. In Germany, Beyer-Westendorf et al reported 
persistence from primary care patients at 180 days of 66.0% 
for rivaroxaban, 60.3% for dabigatran and 58.1% for VKA. At 1 
year corresponding persistence estimates were 53.1%, 47.3% 
and 25.45% respectively. An MPR ≥ was found for 61.4% of 
rivaroxaban and 49.5% of dabigatran patients  . Experience in 
Australia for the period 2006 to 2009 for a sample of 1,108 
patients, mean age 74 years, found that 15% (95% CI: 13-
17%) failed to collect the first repeat warfarin prescription. 
Median persistence time on medication was only 12 months 
(95% CI: 10-13%) with long-term persistence at 33 months at 
26% (95% CI: 23-27%). 
 
Overall, these estimates suggest that by the end of one year 
after the index prescription persistence with warfarin is in the 
range 60 to 70% with a corresponding NOAC rate of 70 to 
80%. By the end of year 2, persistence is likely to be 15 to 
20% lower. Beyond two years is sheer speculation, although it 
would not be unreasonable, given evidence for persistence in 
other chronic disease states, to argue that the overwhelming 
majority of patients have discontinued within 5 years. Given 
the age at which treatment is usually initiated for atrial 
fibrillation, deaths to patients need to be factored in to 
persistence estimates. In the edoxaban pivotal trial, for 
example, 10-8% of patients died before the end of the trial. 
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Under reasons for discontinuation death was given in 3.1% of 
warfarin patients and 2.8% of edoxaban patients. 
 
Adherence patterns add a further dimension. Although not 
captured in any of the pivotal trials, other than reporting time 
in therapeutic range for warfarin, adherence as reported by 
Yao et al., is a potentially important offset to claimed therapy 
gains. While it is often difficult in observational studies to 
distinguish adherence from discontinuation, their additive 
effect on projected model end-points in therapy could be 
significant. 
 
If the majority of patients initiated to an oral anticoagulant 
(OAC) have discontinued therapy, for event related reasons, 
non-event related reasons and death within 4 to 5 years of 
their initial prescription, then it seems rather odd to focus on 
creating projections for discounted direct medical costs and 
utilities over a lifetime horizon. Instead of modeling switching 
and discontinuation behavior over the lifetime of a treatment 
cohort, a more practical and useful approach would be to 
recognize the likelihood of early discontinuation (or switching 
to successor compounds) and generate comparative 
predictions for events and costs for a timeframe that can be 
captured from existing data sources as feedback to formulary 
committees.  
 
There are, in fact, example in the literature over the past 5 
years of cost-effectiveness studies explicitly taking a short-
term modeling approach that focus on clinical outcomes and 
eschew a QALY endpoint 25 26. These models adopt a two-year 
time frame with a Monte Carlo simulation. The claims 
presented are readily evaluable in treatment settings.  QALYs 
are put to one side because of doubts as to their validity with 
observed and calculated utility values varying significantly, 
together with concerns over preference consistency 27. In 
short, if it is possible to commit resources to developing and 
reviewing lifetime cost-per-QALY models is should be 
relatively straightforward to apply those resources to short 
term models that generate evaluable claims. These, at least, 
would have the merit of meeting the standards of normal 
science. 
 
The Genius of the Reference Case 
The genius of the reference case is that it puts to one side 
hypothesis testing, falsification and replication. There is no 
need to demonstrate empirically the worth of a claim. 
Replication is out of the question. Once the NICE appraisal is 
complete, guidance can be drawn up safe in the knowledge 
that they rest on a sound and incontrovertible evidence base. 
Clinical guidance can be implemented safe in the knowledge 
that any challenge or feedback will be impossible. 
 
The virtually unassailable position that adoption of a 
reference case and its putative popularity with the NHS, other 
single payer health systems and model builders in technology 
assessment,   means that there would be a considerable push 
back to recommendations for a defensible assessment 
process.  
 
Whether these systems embraced a reference case model 
(with some rejecting willingness-to-pay thresholds such as 
PHARMAC in New Zealand) in the full recognition of the 
advantages of mandating or recommending non-testable 
modeled claims is an open question. A more reasonable 
interpretation is that they simply followed the crowd: lifetime 
cost-per-utility models were the flavor of the month, so let’s 
hop on the bandwagon. One day, perhaps, the penny will 
drop. 
 
Conclusions 
There are two reasons for being optimistic; for believing that 
at least some practitioners in this discipline will see the penny 
drop in favor of the scientific method. First, the growing 
concern over the failure to replicate clinical claims, 
particularly with outcome switching,  and second, increasing 
pressure from competing manufacturers, physicians and 
patient groups on pharmacy and formulary decision makers 
to justify formulary decisions and to present, at least in the 
US evidence-based value propositions to support product 
adoption 28 29.  The ready access in the US to ‘big healthcare 
data’ offers a ‘relatively’ low cost and timely access to 
administrative claims and electronic records to address the 
question: can we substantiate the claims for that product or 
device? 30 31 32 Together with the ‘supplementary’ question: 
why were the claims made not put in testable form with 
protocols to detail how the claims should be assessed? 
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